Previous Close | 342.59 |
1-Year Change | 55.25% |
6-Months Change | 44.72% |
3-Months Change | 10.88% |
Moving Avg (50d) | 337.32 |
Moving Avg (200d) | 269.62 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 16.1B |
Beta (3-Years) | 0.39 |
Revenue Growth (ttm) | 18.51% |
Net Profit Margin (ttm) | 40.69% |
Return On Assets (ttm) | 12.77% |
EPS (ttm) | 18.13 |
PE Ratio (ttm) | 18.9 |
Dividend Yield | % |
Asset Description: | United Therapeutics Corporation |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2024-08-14 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
349.442 | 359.719 | 366.571 | 376.849 | 393.978 | 411.108 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.